Pharmacokinetic basis of the antiplatelet action of prasugrel. - Wikidata - awgldk - TriplyDB

Pharmacokinetic basis of the antiplatelet action of prasugrel.

Pharmacokinetic basis of the antiplatelet action of prasugrel.

http://www.wikidata.org/entity/Q37927151

about

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls Clopidogrel: the data, the experience, and the controversies.The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers.Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting.P2Y12 Receptors in Tumorigenesis and Metastasis.The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor

P2860

Q26775125-AA49C753-5649-4A8E-911B-448750D37ADD Q30573045-AA82D7BF-F7F6-4BC0-BD38-DBDCAF102C7F Q37462239-897F9879-2679-426D-AD07-9A60B97E60E0 Q38025446-510F38D0-B34A-4917-8940-7BCE970E52E4 Q38151563-A8BA7A15-DA9A-40F4-AA17-733AF6493EC2 Q38177048-F1E89FB7-34EC-45CA-A850-0F2CEA9399DE Q38750444-98C19AB1-3182-48FE-A103-E61A43F7C7BD Q41343370-49C38AC0-9348-4BE8-A752-2E1DC139577C Q49884998-80405DD2-1C1C-45EC-8938-788C7FE0DC32 Q51063040-C88C5752-09CE-4A6D-9988-CF1A75B35E2B Q58070750-969AA566-2D30-4739-9797-DA45E32F318F

P2860

Pharmacokinetic basis of the antiplatelet action of prasugrel.

http://www.wikidata.org/entity/Q37927151

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetic basis of the antiplatelet action of prasugrel.

@en

Pharmacokinetic basis of the antiplatelet action of prasugrel.

@nl

type

label

Pharmacokinetic basis of the antiplatelet action of prasugrel.

@en

Pharmacokinetic basis of the antiplatelet action of prasugrel.

@nl

prefLabel

Pharmacokinetic basis of the antiplatelet action of prasugrel.

@en

Pharmacokinetic basis of the antiplatelet action of prasugrel.

@nl

P1433

Q37927151-C7899B1D-71FA-40E4-8449-96783C71CE7B

P1476

Q37927151-9723BC5E-DAF5-455D-9DE0-7EE27ECE8662

P2093

Q37927151-1FC5C58B-8FE4-4216-9A7D-F3097D16FF5A

Q37927151-F423B78E-C10F-43EA-B8C2-73D746DB0C70

P2860

Q37927151-022E4D64-1A51-49A9-BEF2-E8B3CB99F534

Q37927151-0268C654-F599-4126-A10E-45414F3A93B2

Q37927151-03F8620E-8848-4B4F-8807-F7F65D2DB605

Q37927151-074ADE10-73A0-4F11-BEC7-A9DD1B650C1E

Q37927151-13183094-2A36-46A5-B43D-9916C88BACD4

Q37927151-15994CC6-52A4-4416-A65A-49B9327983D9

Q37927151-1B51C9B2-1AA7-4ED2-828F-A444BE5921DE

Q37927151-21D9723C-295E-444D-88B6-339A04D33854

Q37927151-27C4B74F-169E-41F6-880A-C978B5896E49

Q37927151-28F6E164-A9FA-4140-B226-F54F665C3580

P304

Q37927151-894B369E-ADED-4844-9402-129706B0571F

P31

Q37927151-93DB840F-2452-4545-BF28-6F1CF6C85F10

P356

Q37927151-486207D9-009C-41AB-B4E9-F2864EA05916

P433

Q37927151-5A639530-A325-4352-8B67-67D27B4768FA

P478

Q37927151-81FEABC3-1A20-4002-9DAE-FC9D8510ED2F

P50

Q37927151-833BA516-2681-480E-9019-5F3309B52823

P577

Q37927151-7D8330FD-8BC4-42BC-828A-5C69E84E6141

P5875

Q37927151-6C3DD51A-429D-4EB6-BA03-F1013774CC2E

P698

Q37927151-750DA4C6-4129-477E-9FC0-1BBC7D8291A4

P356

J.1472-8206.2011.00986.X

P1433

Fundamental and Clinical Pharmacology

P1476

Pharmacokinetic basis of the antiplatelet action of prasugrel.

@en

P2093

Karsten Schrör

http://www.w3.org/2001/XMLSchema#string

Kurt Huber

http://www.w3.org/2001/XMLSchema#string

P2860

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting

Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol

Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry

Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

P304

39-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1472-8206.2011.00986.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Jolanta M Siller-Matula

P577

2011-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51623197

http://www.w3.org/2001/XMLSchema#string

P698

21895761

http://www.w3.org/2001/XMLSchema#string